ATOSSA THERAPEUTICS, INC.
Close on Oct 19, 2026
- Market cap
- $22.81M
- P/E (TTM)
- –
- Dividend yield
- –
About Atossa Therapeutics
Pharmaceutical Preparations, SIC 2834
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing medicines for areas of significant unmet medical need in oncology, primarily breast cancer and other breast conditions. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen designed to directly inhibit estrogen receptor signaling, induce estrogen receptor degradation, and promote apoptosis in estrogen receptor-positive breast cancer cells. In addition to breast cancer prevention and treatment across neoadjuvant and adjuvant settings, the company explores the molecule for potential rare disease indications, including Duchenne muscular dystrophy, symptomatic female carriers of the condition, and McCune-Albright syndrome.
The company operates in the United States and has conducted clinical trials in international locations such as Stockholm, Sweden. It maintains principal executive offices in Seattle, Washington. Atossa Therapeutics collaborates with external study groups and relies on third-party suppliers, manufacturers, and clinical research organizations to support its drug development programs.
Summary of the business section of Atossa Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- ATOSSA THERAPEUTICS, INC.
- Founded
- 2009
- Headquarters
- Seattle, WA
- Address
- 1448 Nw Market Street, Suite 500 98107
- Phone
- (206) 588-0256
- Website
- atossatherapeutics.com
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- EY, Seattle, Washington
Stock & identifiers
- Ticker
- ATOS
- Exchange
- Nasdaq
- IPO date
- Nov 8, 2012
- Shares outstanding
- 10M, Jul 31, 2026
- Public float
- $107.15M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-15 reverse, Feb 2, 2026; 1-for-15 reverse, Feb 2, 2026; 1-for-12 reverse, May 14, 2018; 1-for-12 reverse, Apr 20, 2018; 1-for-15 reverse, Nov 14, 2016; 1-for-15 reverse, Aug 26, 2016
- SEC CIK
- 1488039
- CUSIP
- 04962H704
- ISIN
- US04962H7044
- LEI
- 549300QRKP1JTNHD2366
- EIN
- 26-4753208
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Steven C. Quay | President & CEO, Director | 89,521 |
| Mark James Daniel | Chief Financial Officer | 63,000 |
| Heather Rees | Chief Financial Officer | – |
| Richard I. Steinhart | Director | 10,000 |
| Jonathan Finn | Director | 11,666 |
| Tessa Cigler | Director | 10,000 |
| Shu-Chih Chen | Director | 11,483 |
| Stephen J. Galli | Director | 10,006 |
| H. Lawrence Remmel | Director | 12,683 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Dr. Quay | $2.50M | $2.20M | $759.11K | $-12 | – |
| FY2024 Dr. Quay | $2.76M | $3.02M | $1.15M | $79 | – |
| FY2023 Dr. Quay | $2.36M | $2.65M | $1.41M | $-67 | – |
| FY2022 Dr. Quay | $3.16M | $2.97M | $1.53M | $-44 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Corporate history
Events identified from SEC filings